share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股sec公告 ·  04/16 16:12
Moomoo AI 已提取核心訊息
On April 16, 2024, Clene Inc. announced the release of clinical trial results for its CNM-Au8 treatment in the VISIONARY-MS long-term extension trial for multiple sclerosis (MS). The results were presented at the 2024 American Academy of Neurology Annual Meeting and suggest that CNM-Au8 may aid in repair and remyelination in MS patients. The company shared this information through a presentation and a poster on its website, and also issued a press release. These materials were furnished as exhibits to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. emphasized that the information provided, including the exhibits, is not to be considered filed for regulatory purposes nor incorporated by reference into any of their SEC filings.
On April 16, 2024, Clene Inc. announced the release of clinical trial results for its CNM-Au8 treatment in the VISIONARY-MS long-term extension trial for multiple sclerosis (MS). The results were presented at the 2024 American Academy of Neurology Annual Meeting and suggest that CNM-Au8 may aid in repair and remyelination in MS patients. The company shared this information through a presentation and a poster on its website, and also issued a press release. These materials were furnished as exhibits to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. emphasized that the information provided, including the exhibits, is not to be considered filed for regulatory purposes nor incorporated by reference into any of their SEC filings.
2024年4月16日,Clene Inc.宣佈在VISIONARY-MS多發性硬化症(MS)長期延期試驗中公佈其CNM-Au8治療的臨床試驗結果。研究結果已在2024年美國神經病學會年會上公佈,表明CNM-Au8可能有助於多發性硬化症患者的修復和髓鞘再生。該公司通過其網站上的演示和海報分享了這些信息,還發布了新聞稿。這些材料是作爲該公司向美國證券交易委員會提交的8-K表最新報告的證物提供的。Clene Inc. 強調,所提供的信息,包括證物,不應被視爲出於監管目的提交的,也不得以引用方式納入其向美國證券交易委員會提交的任何文件中。
2024年4月16日,Clene Inc.宣佈在VISIONARY-MS多發性硬化症(MS)長期延期試驗中公佈其CNM-Au8治療的臨床試驗結果。研究結果已在2024年美國神經病學會年會上公佈,表明CNM-Au8可能有助於多發性硬化症患者的修復和髓鞘再生。該公司通過其網站上的演示和海報分享了這些信息,還發布了新聞稿。這些材料是作爲該公司向美國證券交易委員會提交的8-K表最新報告的證物提供的。Clene Inc. 強調,所提供的信息,包括證物,不應被視爲出於監管目的提交的,也不得以引用方式納入其向美國證券交易委員會提交的任何文件中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息